RxDoctor Payments Data

Hayan Al Maluli, MD

Cardiovascular Disease · Minneapolis, MNNPI 1972814473

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $22,710 of the $27,364 with a category attached, or 83.0%. United Therapeutics Corporation accounts for 75.8% of it on its own, with 3 other manufacturers making up the rest.

$27,364in general payments, 2019–2025

Across 44 payments — averaging $621.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • United Therapeutics Corporation$21K
  • Actelion Pharmaceuticals US, Inc.$6K
  • Abbott$941
  • Boston Scientific$64
$43,611in research payments, 2019–2025

Across 30 payments — averaging $1453.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • CSL Behring$25K
  • Abbott$19K

What the payments were for

  • Speaking & faculty fees$22,71083%
  • Travel & lodging$4,00715%
  • Food & beverage$6482%

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,364 in reported general payments places this provider in the 80th percentile of 451 cardiovascular disease providers in Minnesota.

See all cardiovascular disease providers in Minnesota →

Medicare billing

Part B allowed, 2024
$99,299
Medicare patients
920
Services billed
1,614

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UptraviSelexipag22$802,929
OpsumitMacitentan58$741,335
Tyvaso DpiTreprostinil21$510,036
WinrevairSotatercept-Csrk11$260,895
AdempasRiociguat15$209,882
EliquisApixaban178$190,775
Ambrisentan32$143,258
EntrestoSacubitril/Valsartan45$46,037
JardianceEmpagliflozin49$39,010
FarxigaDapagliflozin Propanediol17$27,379
XareltoRivaroxaban18$26,938
Tadalafil48$24,107
Sildenafil Citrate89$21,106
OzempicSemaglutide13$16,293
MounjaroTirzepatide13$14,616

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit$5,609$1,544,26480 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 451 cardiovascular disease providers in Minnesota.

Other cardiovascular disease in Minneapolis

See the full list for Minnesota →

Where these figures come from

Is this you, or does something look wrong? →